mercaptopurine and Carcinoma--Squamous-Cell

Thiopurines are the mainstay of treatment for patients with inflammatory bowel disease (IBD). Thiopurine therapy increases the risk of nonmelanoma skin cancers (NMSCs) in organ transplant patients. The data on NMSC in patients with IBD on thiopurines is conflicting.. We searched electronic databases for full journal articles reporting on the risk of developing NMSC in patients with IBD on thiopurine and hand searched the reference lists of all retrieved articles. Pooled adjusted hazard ratios and 95% confidence intervals (CIs) were determined using a random-effects model. Publication bias was assessed using Funnel plots and Egger's test. Heterogeneity was assessed using Cochran's Q and the I(2) statistic.. Eight studies involving 60,351 patients provided data on the risk of developing NMSC in patients with IBD on thiopurines. The pooled adjusted hazards ratio of developing NMSC after exposure to thiopurines in patients with IBD was 2.28 (95% CI: 1.50 to 3.45). There was significant heterogeneity (I(2)=76%) between the studies but no evidence of publication bias. Meta regression analysis suggested that the population studied (hospital-based vs. population-based) and duration of follow-up contributed significantly to heterogeneity. Grouping studies based on population studied and duration showed higher hazard rations in hospital-based and shorter duration studies.. The risk of developing NMSC in patients with IBD on thiopurines is only modestly elevated. The difference in pooled risk between population-based and hospital-based studies suggests the possibility that ascertainment bias could have contributed to this increased risk.

Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cohort Studies; Confidence Intervals; Databases, Factual; Education, Medical, Continuing; Female; Humans; Immunosuppressive Agents; Incidence; Inflammatory Bowel Diseases; Male; Mercaptopurine; Prognosis; Proportional Hazards Models; Regression Analysis; Risk Assessment; Skin Neoplasms; United Kingdom

Thymic carcinoma associated with acute monocyte leukemia (AMoL) and a history of choriocarcinoma was diagnosed in a 58-year-old female. We found no other such case in a literature search. She was first treated with DCMP therapy: daunorubicin, cytosine arabinoside, 6MP-riboside, and prednisolone against AMoL. After induction chemotherapy, complete AMoL remission was attained. Chest CT scan after chemotherapy revealed regression of the mediastinal tumor. Resection of the tumor included the left upper lobe of the lung, phrenic nerve and pericardium. Pathological diagnosis showed poorly or moderately differentiated squamous cell carcinoma. Although the patient died of pneumonia during chemotherapy for relapsed AMoL, chest X-ray and CT revealed no recurrence of the mediastinal tumor after the original operation. Judging from this case and other successful cases of chemotherapy, we feel that intensive chemotherapy may be a beneficial strategy against thymic carcinoma.

Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Choriocarcinoma; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Monocytic, Acute; Mercaptopurine; Middle Aged; Neoplasms, Multiple Primary; Prednisolone; Thymus Neoplasms; Uterine Neoplasms

This review highlights the most important recent advances in the chemotherapeutic management of patients with squamous cell carcinoma of the head and neck. Previous chemotherapy trials must be interpreted with caution in the absence of information concerning important prognostic variables, such as prior treatment, nutritional and performance status, and the heterogeneity of primary sites. In patients who have recurrent or metastatic disease, methotrexate, platinum, and bleomycin are three active drugs when used as single agents. There is no evidence that high dose methotrexate therapy is superior to more conventional weekly intravenous administration of methotrexate in the treatment of recurrent disease. Platinum is a new agent that has demonstrated activity against hematogenous as well as regional disease. In the absence of evidence of a dose-response curve for platinum, the lower dosage schedules that can be used with acceptable toxicity on an outpatient basis should be selected. Combination chemotherapy has resulted in a high proportion of objective responders and approximately 20 per cent complete remissions with any of several platinum containing regimens. However, the median duration of response remains short, and none of the combination drug programs has as yet been established to be superior to single agent chemotherapy in a randomized trial. Both single agent and combination chemotherapy programs have been used prior to initial surgery or radiation in patients with advanced inoperable but nonmetastatic disease. Despite dramatically higher response rates over those obtained with the same drugs used in recurrent disease, there is as yet no evidence that chemotherapy given in this manner has resulted in improved disease free or overall survival compared with local treatment alone. Similarly, the use of adjuvant chemotherapy following tumor clearance to eradicate potential micrometastatic disease is currently under investigation and cannot be recommended in the absence of a controlled trial. This article reviews the clinical trials currently in progress both for patients with recurrent squamous cell carcinoma of the head and neck and those with advanced local or regional disease.

Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Mechlorethamine; Mercaptopurine; Methotrexate; Procarbazine; Vinblastine

Topics: Acute Disease; Administration, Oral; Adult; Age Factors; Body Weight; Burkitt Lymphoma; Carcinoma, Squamous Cell; Child; Choriocarcinoma; Drug Combinations; Female; Folic Acid Antagonists; Humans; Injections, Intramuscular; Injections, Intravenous; Leukemia; Mercaptopurine; Methotrexate; Prednisone; Pregnancy; Time Factors; Vincristine

This review highlights the most important recent advances in the chemotherapeutic management of patients with squamous cell carcinoma of the head and neck. Previous chemotherapy trials must be interpreted with caution in the absence of information concerning important prognostic variables, such as prior treatment, nutritional and performance status, and the heterogeneity of primary sites. In patients who have recurrent or metastatic disease, methotrexate, platinum, and bleomycin are three active drugs when used as single agents. There is no evidence that high dose methotrexate therapy is superior to more conventional weekly intravenous administration of methotrexate in the treatment of recurrent disease. Platinum is a new agent that has demonstrated activity against hematogenous as well as regional disease. In the absence of evidence of a dose-response curve for platinum, the lower dosage schedules that can be used with acceptable toxicity on an outpatient basis should be selected. Combination chemotherapy has resulted in a high proportion of objective responders and approximately 20 per cent complete remissions with any of several platinum containing regimens. However, the median duration of response remains short, and none of the combination drug programs has as yet been established to be superior to single agent chemotherapy in a randomized trial. Both single agent and combination chemotherapy programs have been used prior to initial surgery or radiation in patients with advanced inoperable but nonmetastatic disease. Despite dramatically higher response rates over those obtained with the same drugs used in recurrent disease, there is as yet no evidence that chemotherapy given in this manner has resulted in improved disease free or overall survival compared with local treatment alone. Similarly, the use of adjuvant chemotherapy following tumor clearance to eradicate potential micrometastatic disease is currently under investigation and cannot be recommended in the absence of a controlled trial. This article reviews the clinical trials currently in progress both for patients with recurrent squamous cell carcinoma of the head and neck and those with advanced local or regional disease.

Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Mechlorethamine; Mercaptopurine; Methotrexate; Procarbazine; Vinblastine

Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; History, 16th Century; Humans; Hydrazines; Injections, Intravenous; Laryngeal Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Neoplasms; Prognosis; Time Factors; Tongue Neoplasms; Vinblastine

Topics: Adenocarcinoma; Anemia; Bone Marrow Diseases; Carcinoma, Squamous Cell; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Colonic Neoplasms; Humans; Leukopenia; Lung Neoplasms; Mercaptopurine; Nausea; Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Thrombocytopenia; Vomiting

Patients with inflammatory bowel diseases may have higher incidences of non-melanoma skin cancers and non-Hodgkin lymphoma, potentially linked to underlying disease and treatments. This analysis assessed incidence rates of these malignancies in Japanese patients with ulcerative colitis or Crohn's disease, and their association with thiopurine and/or anti-tumor necrosis factor-α treatment, using data from a nationwide administrative database in Japan.. Patients diagnosed with inflammatory bowel disease without malignancy were identified from the Medical Data Vision database. Incident cases of non-melanoma skin cancers and non-Hodgkin lymphoma diagnosed after prescription of thiopurine and/or anti-tumor necrosis factor-α were identified between April 2008 and January 2018. Age- and sex-adjusted incidence rate ratios were calculated relative to the total treated patient population.. A total of 75 673 eligible patients were identified at the index date. Thiopurine prescription with or without anti-tumor necrosis factor-α agents increased incidence rate ratios for non-melanoma skin cancers relative to the overall population (3.39 and 4.03, respectively). There were no notable differences in non-Hodgkin lymphoma incidence relative to the total population in any treatment subgroup, regardless of prescription of thiopurine and/or anti-tumor necrosis factor-α (all incidence rate ratios, ~1).. There is no evidence for an increased incidence of non-Hodgkin lymphoma attributable to thiopurine or anti-tumor necrosis factor-α treatment in Japanese patients with inflammatory bowel disease. The impact of racial differences on non-Hodgkin lymphoma incidences should be considered. Thiopurine therapy may be a risk factor for non-melanoma skin cancers in Japanese patients.

Topics: Adalimumab; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies; Databases, Factual; Drug Therapy, Combination; Female; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Incidence; Infliximab; Japan; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Middle Aged; Proportional Hazards Models; Risk Factors; Skin Neoplasms; Tumor Necrosis Factor-alpha

Topics: Aged; Azathioprine; Carcinoma, Squamous Cell; Crohn Disease; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Mercaptopurine; Neoplasm Invasiveness; Uterine Cervical Neoplasms

A 67-year-old patient with chronic myeloid leukemia for 4 years rapidly developed multiple squamous-cell carcinomas on the scalp. We discuss the role of chemotherapy, chronic immunosuppression, chronic sun exposure and of possible genetic factors.

Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Immunocompromised Host; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Neoplasms, Multiple Primary; Scalp; Skin Neoplasms; Sunlight

Thirteen consecutive patients presenting with squamous cell carcinoma in the postcricoid region (PCC) are studied and details of their age, sex, TNM status, treatment and results are analysed. Follow-up ranges from 33 months to 11 years. Three patients presented with cervical node involvement and 2 of these remain disease free without surgical intervention, at 33 months and 9 years. The principal treatment policy has been the combination of multi-agent chemotherapy with radical radiotherapy, reserving wide excision surgery for patients with residual or recurrent carcinoma. Only 4 patients underwent pharyngolaryngectomy, one radical neck dissection was performed and 7 of the 13 patients have remained free of disease for more than 3 years.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Hydroxyurea; Laryngeal Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Vincristine

Twenty-seven evaluable patients with advanced head and neck squamous carcinoma were treated with a polychemotherapeutic regimen described in 1975 by Price et al. Chemotherapy consisted of vincristine, adriamycin, bleomycin, methotrexate, 5-fluorouracil, hydroxyurea, 6-mercaptopurine and citrovorum factor administered sequentially. One complete remission, 4 partial remissions, 7 minor responses were obtained for a total of 12/77 (44%) objective responses. Toxicity was acceptable. The results obtained were not better than those observed with less complicated regimens administrable on an outpatient basis.

Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Leucovorin; Male; Mercaptopurine; Methotrexate; Middle Aged; Vincristine

Cells obtained from the Nettesheim lung carcinoma of DBA/2 mice, a heterogenous population grown s.c., were cultured as monolayers. These cells were serially subcultured and cloned twice, and a clone was selected for further study. This clone produced malignant tumors at the injected site when injected s.c. into male DBA/2 or C57BL/L x DBA/2 F1 mice. Referred as KLN205, this cell line had the highest rate of lung colony formation on i.v. injection. It was subcultured for over 15 generations, and its cytological characteristics were investigated. The s.c. and lung colony growth were examined histologically. The effects of treatment with two antimetabolite drugs, arabinosyl-6-mercaptopurine (NSC 406021) and 6-selenoguanosine (NSC 137679) were determined in culture and in vivo. The former was relatively ineffective; the latter was very effective both in vivo and in vitro. Several drugs used clinically for the treatment of lung cancer were also tested. This established and characterized cell line is proposed as a potential model for testing other chemotherapeutic treatments.

Topics: Animals; Carcinoma, Squamous Cell; Cell Division; Clone Cells; Guanosine; Lung Neoplasms; Male; Mercaptopurine; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Organoselenium Compounds; Selenium; Transplantation, Homologous; Transplantation, Isogeneic

The effects of 6-thioguanine on purine biosynthesis and cell viability have been examined in H.Ep. 2 cells grown in culture. Toxicity is not reversed by aminoimidazolecarboxamide, suggesting that inhibition of purine biosynthesis de novo is not the sole mechanism of toxicity. Also, 6-(methylmercapto)purine ribonucleoside, a potent inhibitor of purine biosynthesis de novo, produces more marked reductions in cellular pools of purines than does 6-thioguanine without killing cells. There is no apparent inhibition by 6-thioguanosine 5'-monophosphate of other enzymes leading to the synthesis of guanosine 5'-triphosphate as determined in whole cells by measurements of radioactive hypoxanthine or guanine incorporation. Inhibition of DNA synthesis by 1 mM thymidine protects cells from 6-mercaptopurine or 6-thioguanine but fails to protect cells from 8-azaguanine toxicity. On the other hand, inhibition of RNA synthesis by 6-azauridine plus deoxycytidine protects cells against 8-azaguanine but does not protect against 6-thioguanine or 6-mercaptopurine toxicity. In agreement with the in vitro data, arabinosylcytosine (a potent inhibitor of DNA synthesis) fails to protect mice against 8-azaguanine but has previously been shown to protect mice from 6-mercaptopurine or 6-thioguanine toxicity. The results support the hypotheses of others that incorporation into DNA (as 6-thioguanine nucleotide) is a mechanism of toxicity for these thiopurines, whereas 8-azaguanine is toxic due to its incorporation into RNA.

Topics: Azaguanine; Azauridine; Carcinoma, Squamous Cell; Cell Line; Cell Survival; Cytarabine; Deoxycytidine; DNA, Neoplasm; Guanine; Hypoxanthines; Imidazoles; Mercaptopurine; Methylthioinosine; Purines; RNA, Neoplasm; Thioguanine; Thymidine

Topics: Animals; Carcinoma, Squamous Cell; Cell Line; Deoxyribonucleosides; DNA, Neoplasm; Drug Resistance; Guanine; Humans; Hypoxanthines; Leukemia L1210; Mercaptopurine; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasms, Experimental; Pentosyltransferases; Thioguanine

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Aza Compounds; Azaguanine; Carcinoma, Squamous Cell; Cell Line; Cells, Cultured; Drug Resistance; Humans; Hypoxanthines; Imidazoles; Inosine; Leukemia L1210; Mercaptopurine; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Pentosyltransferases; Phosphotransferases; Purines

Topics: Adenine Nucleotides; Carbon Isotopes; Carcinoma, Squamous Cell; Cell Line; Cells, Cultured; Drug Resistance; Guanine Nucleotides; Humans; Hypoxanthines; Mercaptopurine; Pentosyltransferases; Phosphotransferases; Purine Nucleotides; Purine-Pyrimidine Metabolism, Inborn Errors; Sulfur Isotopes

Topics: Adenine Nucleotides; Adult; Animals; Antibiotics, Antineoplastic; Arabinose; Carcinoma, Squamous Cell; Cricetinae; Dogs; Humans; Hypoxanthines; Kidney; Leukemia, Lymphoid; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mice; Middle Aged; Neoplasms; Nucleosides; Nucleotidases; Nucleotides; Phosphorus; Rabbits; Sulfur Isotopes; Time Factors; Tritium

Topics: Acetazolamide; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Diuretics; Female; Furosemide; Male; Melphalan; Mercaptopurine; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Phosphines; Rats; Sarcoma 180; Sarcoma, Experimental; Serotonin

Topics: Autoradiography; Carbon Isotopes; Carcinoma, Squamous Cell; Cell Line; Chemical Phenomena; Chemistry; Chromatography, Thin Layer; Electrophoresis; Guanine Nucleotides; Humans; Hydrolysis; Mercaptopurine; Metabolism; Methionine; Methylation; Paper; Pentosephosphates; Phosphoric Acids; Phosphoric Monoester Hydrolases; Purines; Ribonucleotides; Ribose; Sulfides; Sulfur; Sulfur Isotopes; Thioguanine; Transferases; Venoms

Topics: Alkaline Phosphatase; Aminopterin; Azaguanine; Bromodeoxyuridine; Carcinoma, Squamous Cell; Cell Line; Chromosomes; Clone Cells; Culture Techniques; Enzyme Induction; Humans; Mercaptopurine; Mouth Neoplasms; Sulfhydryl Compounds

Topics: Acridines; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Carcinoma, Squamous Cell; Cell Division; Culture Techniques; Dactinomycin; Humans; Mercaptopurine; Mice; Nasopharyngeal Neoplasms; Neoplasm Proteins; Seeds

Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Benz(a)Anthracenes; Busulfan; Carcinoma, Squamous Cell; Chlorambucil; Cortisone; Cyclophosphamide; Dactinomycin; Estradiol; Female; Fluorouracil; Hydroxyurea; Mercaptopurine; Methotrexate; Mice; Mitomycins; Neoplasms, Experimental; Nitrogen Mustard Compounds; Nitroso Compounds; Papilloma; Skin Neoplasms; Testosterone; Triethylenemelamine

Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dactinomycin; Female; Fluorouracil; Gonadal Steroid Hormones; Hodgkin Disease; Humans; Hydrazines; Leukemia; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mesenchymoma; Methotrexate; Multiple Myeloma; Nitrogen Mustard Compounds; Ovarian Neoplasms; Pregnancy; Prostatic Neoplasms; Steroids; Testicular Neoplasms; Urethane; Vinblastine; Vincristine; Wilms Tumor

Topics: Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Ascorbic Acid; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Synergism; Fluorouracil; Glucocorticoids; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lectins; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Mesothelioma; Methotrexate; Phenylbutazone; Pleural Neoplasms; Thiotepa; Vinblastine

Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Colchicine; Cyclophosphamide; Drug Synergism; Fluorouracil; Humans; Hydrazines; Injections, Intravenous; Mechlorethamine; Mercaptopurine; Methotrexate; Thiotepa; Vinblastine

Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Dactinomycin; Drug Synergism; Humans; Lung Neoplasms; Mercaptopurine; Methotrexate; Mitomycins; Neoplasm Metastasis; Radiotherapy Dosage; Triaziquone

Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Synergism; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Vinblastine

Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Synergism; Fluorouracil; Humans; Hydrazines; Injections, Intravenous; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Neoplasm Metastasis; Pleural Neoplasms; Vinblastine

Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Drug Synergism; Female; Fluorouracil; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lung Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Vinblastine

Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Synergism; Fluorouracil; Humans; Hydrazines; Lung Neoplasms; Mercaptopurine; Mesothelioma; Methotrexate; Neoplasm Metastasis; Vinblastine

Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Drug Synergism; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lectins; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Mouth Neoplasms; Neoplasm Metastasis; Pharyngeal Neoplasms; Urogenital Neoplasms; Vinblastine

Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Betamethasone; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lectins; Lung Neoplasms; Male; Mechlorethamine; Mercaptopurine; Methotrexate; Middle Aged; Pleural Neoplasms; Sarcoma; Vinblastine

Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Culture Techniques; Flavonoids; Fluorouracil; HeLa Cells; Humans; Lung Neoplasms; Melphalan; Mercaptopurine; Methods; Mitomycins; Neoplasms; Rectal Neoplasms; Stomach Neoplasms

Topics: Carcinoma, Squamous Cell; Chromatography, Paper; Culture Techniques; Glucosyltransferases; Humans; Mercaptopurine; Nucleosides; Nucleotides

Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Culture Techniques; Hexokinase; Mercaptopurine; Nucleosides; Phosphotransferases; Purines; Sulfur Isotopes; Yeasts

Topics: Adenine; Animals; Antimetabolites; Antineoplastic Agents; Azaserine; Carcinoma, Squamous Cell; Glycine; Hypoxanthines; Imidazoles; Leukemia L1210; Mercaptopurine; Nucleotides; Pharmacology; Purines; Research; Ribonucleotides; Thioguanine; Tissue Culture Techniques; Xanthines

Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Azaserine; Carcinoma, Squamous Cell; Chelating Agents; Cortisone; Leucine; Mercaptopurine; Mice; Neoplasms; Neoplasms, Experimental; Rats; Research; Sarcoma 180; Streptomycin; Thioguanine; Transplantation

Topics: Carcinoma; Carcinoma, Squamous Cell; Humans; Mercaptopurine; Purines

Topics: Carcinoma; Carcinoma, Squamous Cell; Humans; Mercaptopurine; Reproduction

Topics: Adenine; Animals; Antimetabolites; Carcinoma; Carcinoma, Squamous Cell; Humans; Mercaptopurine; Neoplasms; Neoplasms, Experimental